Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED

Evaluation of the Atlas Genetics io® CTNG System

NCT03071510 · View on ClinicalTrials.gov ↗

Study Summary

Atlas Genetics io® system results are compared with those obtained from comparator devices.

Interventions

  • DEVICE Atlas Genetics io® system

Study Locations (10)

North Carolina

  • University of North Carolina at Chapel Hill — Chapel Hill
  • Wake Forest Center for Reproductive Medicine — Greensboro

Alabama

  • University of Alabama — Birmingham

California

  • AIDS Healthcare Foundation — Los Angeles

Indiana

  • Indiana University — Indianapolis

Louisiana

  • Louisiana State University — New Orleans

Maryland

  • Johns Hopkins University — Baltimore

Mississippi

  • University of Mississippi — Jackson

Pennsylvania

  • Planned Parenthood Southeastern Pennsylvania — Philadelphia

Trial Details

FieldValue
Enrollment Target 7,128 participants
Start Date 2017-05-18
Est. Completion 2019-08-30

Sponsor

Binx Health Limited

1 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03071510

The ClinicalTrials.gov registry entry for NCT03071510 describes a study currently listed as completed. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 7,128 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Binx Health Limited, which has 1 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 2 conditions, with Gonorrhea appearing as the primary indexed condition, and to 1 intervention — of which Atlas Genetics io® system is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT03071510 reports 10 study locations spanning 9 distinct geographic areas — top geographies include North Carolina, Alabama, California. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT03071510 about?

NCT03071510 is a clinical study titled "Evaluation of the Atlas Genetics io® CTNG System". Atlas Genetics io® system results are compared with those obtained from comparator devices.

What is the current status of trial NCT03071510?

This trial is currently completed. The enrollment target is 7,128 participants. The study started on 2017-05-18. Estimated completion is 2019-08-30.

What conditions does trial NCT03071510 study?

This clinical trial studies the following conditions: Gonorrhea, Chlamydia Trachomatis. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT03071510?

The interventions under investigation include: Atlas Genetics io® system (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT03071510?

This trial is sponsored by Binx Health Limited, which has 1 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT03071510 being conducted?

This trial has 10 study locations across Alabama, California, Indiana, Louisiana, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial